Profile - To The Moon

岚宝贝

Posts · 1Posts · 1
Following · 0Following · 0
Followers · 0Followers · 0

- 岚宝贝岚宝贝
  ·2020-12-19
  ?
  Jiakosi-B has a winning rate of 15% for one lot, and you can secure one lot if you subscribe for 50 lots
  12月18日，加科思公布发售价及配股结果。公告显示，加科思-B每股定价14港元；加科思-B一手中签率15%，申购50手稳中一手。此外，香港公开发售和国际配售均获得超额认购。其中，香港公开认购倍数接近3
  Jiakosi-B has a winning rate of 15% for one lot, and you can secure one lot if you subscribe for 50 lots
  3.41K 1
  3
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3569399229123653","uuid":"3569399229123653","gmtCreate":1606305563226,"gmtModify":1606573677153,"name":"岚宝贝","pinyin":"lbblanbaobei","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/bc16978a96a5a751c5f1103c3648c35b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":485,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":397729753,"gmtCreate":1608356301872,"gmtModify":1704974683741,"author":{"id":"3569399229123653","authorId":"3569399229123653","name":"岚宝贝","avatar":"https://static.tigerbbs.com/bc16978a96a5a751c5f1103c3648c35b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569399229123653","authorIdStr":"3569399229123653"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/397729753","repostId":"1117228784","repostType":2,"repost":{"id":"1117228784","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1608261171,"share":"https://ttm.financial/m/news/1117228784?lang=en_US&edition=fundamental","pubTime":"2020-12-18 11:12","market":"hk","language":"zh","title":"Jiakosi-B has a winning rate of 15% for one lot, and you can secure one lot if you subscribe for 50 lots","url":"https://stock-news.laohu8.com/highlight/detail?id=1117228784","media":"老虎资讯综合","summary":"12月18日，加科思公布发售价及配股结果。公告显示，加科思-B每股定价14港元；加科思-B一手中签率15%，申购50手稳中一手。此外，香港公开发售和国际配售均获得超额认购。其中，香港公开认购倍数接近3","content":"<p>On December 18, Jiakosi announced the offer price and allotment results. The announcement shows that,<b>Garcos-B is priced at HK $14 per share; The winning rate of Jiakosi-B is 15%, and the purchase of 50 lots is stable.</b></p><p>In addition, both the Hong Kong Public Offering and the International Placing were oversubscribed. Among them, the Hong Kong public subscription multiple is close to 300 times, and the international offering subscription multiple is close to 11 times.</p><p>According to the announcement,<b>Jiakosi-B issued a total of 96.4761 million shares.</b>Based on the pricing of HK $14 per share,<b>The net financing of this IPO was HK $1.263 billion. If the over-allotment option is fully exercised, the company will raise an additional approximately HK $195 million, and the company's shares will be officially traded on December 21 (next Monday).</b></p><p><img src=\"https://static.tigerbbs.com/c2f940c5d32140b8d862248d723d299a\" tg-width=\"707\" tg-height=\"550\"><b>Distribution result:</b></p><p><ul><li>For each lot (300 shares) in Group A, the funds required for subscription are HK $4,242.32;<b>The winning rate of one hand is 15%, and the purchase of 50 lots is stable;</b></li><li>The head of Group B is 450,000 shares (1,500 lots), and the funds required for subscription are 6,363,485.10;<b>The leader of Group B was allocated 21 lots (6,300 shares), of which 321 people received one more lot.</b></li><li>Head hammer flies 72 pictures,<b>195 lots (58,500 shares) were allocated.</b></li></ul><img src=\"https://static.tigerbbs.com/8f973abe132dabd76f878fcecee2383a\" tg-width=\"676\" tg-height=\"899\"><img src=\"https://static.tigerbbs.com/acd8ad2ecba6fe4811ef5db2ec2ebcc4\" tg-width=\"647\" tg-height=\"314\">According to the prospectus, among the 96.4761 million shares issued by Jiakosi, 9.648 million are planned to be publicly offered in Hong Kong, accounting for 10% of the shares issued this time; 86.8281 million shares were placed internationally, accounting for 90% of the total number of shares issued this time.</p><p><b>After adjustment of the callback mechanism,</b>38.592 million shares were called back from the international placement to the public offering in Hong Kong.<b>Eventually,</b></p><p><ul><li><b>48.24 million shares were publicly offered in Hong Kong, accounting for about 50% of the shares issued this time</b>(before the exercise of the Over-allotment Option)<b>；</b></li><li><b>International placement of 48.2361 million shares, accounting for approximately 50% of the shares issued this time</b>(before the exercise of the Over-allotment Option)<b>；</b></li></ul><b>In terms of financing purposes,</b>The company's net proceeds of approximately HK $1,263.1 million will be used for the following purposes:</p><p><ul><li>Approximately 88.0% are mainly used for clinical development and commercialization of products;</li><li>8.0% for the construction of GMP compliant in-house production facilities;</li><li>4.0% is used for the company's general corporate and working capital purposes.</li></ul><b>As for financial data,</b>During the Track Record Period, the Company's products have not been approved for commercial sale and therefore did not generate any revenue. Net loss increased from RMB156 million in 2018 to RMB426 million in 2019.</p><p><img src=\"https://static.tigerbbs.com/98eacea48373e0e12e465967c7a1e0a9\" tg-width=\"673\" tg-height=\"811\"></p><p><b>Industry terms,</b>The global oncology drug market has developed significantly over the past few years and is expected to further expand at a faster rate. This is mainly driven by increasing cancer incidence, increasing affordability and technological advancements in treatment modalities.</p><p>The development of targeted therapies has ushered in a new era of tumor treatment characterized by enhanced specificity and efficacy. In addition, other new tumor drug treatments have emerged in recent years and have shown great clinical benefits, including tumor immunotherapy and various combination therapies.</p><p><img src=\"https://static.tigerbbs.com/d174af091109bef09a8e18a14b37491c\" tg-width=\"919\" tg-height=\"430\"></p><p>Among them, SHP2 promotes the proliferation of cancer cells and plays an important role in the process of developing resistance to targeted therapies. SHP2 inhibition as a monotherapy may be effective for cancers with specific alterations. It is estimated that in 2019, the overall annual incidence of patients with advanced solid tumors due to EGFR amplification, KRAS amplification, KRAS G12C mutation, KRASG12A mutation, Class 3 BRAF mutation and NF1 loss of function was approximately 1.2 million and approximately 394,700 worldwide and China, respectively, who are expected to benefit from SHP2-targeted inhibitor monotherapy.</p><p><img src=\"https://static.tigerbbs.com/12672c9f00673ea28225be4042bfacce\" tg-width=\"826\" tg-height=\"524\"></p><p><b>As for cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of Offer Shares available for subscription at the Offer Price, totaling approximately US $60 million, including LAV Funds, Matthews Funds, Hudson's Bay Capital Octagon Investments Master Fund LP, Superstring Capital Master Fund LP and Sage Partners Master Fund.</p><p><b>Company Introduction</b></p><p>It is reported that Garcos, founded in 2015, is a clinical-stage pharmaceutical company focusing on the independent discovery and development of innovative tumor therapies. Its main business focuses on the research of small molecule innovative drugs in the anti-tumor field with independent intellectual property rights, focusing on tumor immunity, drug-resistant antibiotics, geriatric diseases and other directions.</p><p>From the perspective of R&D pipeline, Jiakosi has a total of 16 product pipelines, of which 5 indications and 3 products have entered the clinical stage, and 1 has entered clinical phase IIa. According to the prospectus, the faster-progressing drug development projects in the Garcos product line are SHP2 inhibitors, including JAB-3068 and JAB-3312, of which JAB-3068 has entered Phase IIa.</p><p>It is worth noting that the shareholder lineup of Jiakosi. The company's founder, Dr. Wang Yinxiang, was once<a href=\"https://laohu8.com/S/300558.SZ.SZ\">Beida Pharmaceuticals</a>One of the co-founders of. At the same time, the company is favored by star institutional investors, including Shengde Pharmaceutical Company (holding 17.92% of the shares), Hillhouse Capital (holding 8.57% of the shares), Qiming Venture Capital, Eli Lilly LAV, etc.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiakosi-B has a winning rate of 15% for one lot, and you can secure one lot if you subscribe for 50 lots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiakosi-B has a winning rate of 15% for one lot, and you can secure one lot if you subscribe for 50 lots\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2020-12-18 11:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On December 18, Jiakosi announced the offer price and allotment results. The announcement shows that,<b>Garcos-B is priced at HK $14 per share; The winning rate of Jiakosi-B is 15%, and the purchase of 50 lots is stable.</b></p><p>In addition, both the Hong Kong Public Offering and the International Placing were oversubscribed. Among them, the Hong Kong public subscription multiple is close to 300 times, and the international offering subscription multiple is close to 11 times.</p><p>According to the announcement,<b>Jiakosi-B issued a total of 96.4761 million shares.</b>Based on the pricing of HK $14 per share,<b>The net financing of this IPO was HK $1.263 billion. If the over-allotment option is fully exercised, the company will raise an additional approximately HK $195 million, and the company's shares will be officially traded on December 21 (next Monday).</b></p><p><img src=\"https://static.tigerbbs.com/c2f940c5d32140b8d862248d723d299a\" tg-width=\"707\" tg-height=\"550\"><b>Distribution result:</b></p><p><ul><li>For each lot (300 shares) in Group A, the funds required for subscription are HK $4,242.32;<b>The winning rate of one hand is 15%, and the purchase of 50 lots is stable;</b></li><li>The head of Group B is 450,000 shares (1,500 lots), and the funds required for subscription are 6,363,485.10;<b>The leader of Group B was allocated 21 lots (6,300 shares), of which 321 people received one more lot.</b></li><li>Head hammer flies 72 pictures,<b>195 lots (58,500 shares) were allocated.</b></li></ul><img src=\"https://static.tigerbbs.com/8f973abe132dabd76f878fcecee2383a\" tg-width=\"676\" tg-height=\"899\"><img src=\"https://static.tigerbbs.com/acd8ad2ecba6fe4811ef5db2ec2ebcc4\" tg-width=\"647\" tg-height=\"314\">According to the prospectus, among the 96.4761 million shares issued by Jiakosi, 9.648 million are planned to be publicly offered in Hong Kong, accounting for 10% of the shares issued this time; 86.8281 million shares were placed internationally, accounting for 90% of the total number of shares issued this time.</p><p><b>After adjustment of the callback mechanism,</b>38.592 million shares were called back from the international placement to the public offering in Hong Kong.<b>Eventually,</b></p><p><ul><li><b>48.24 million shares were publicly offered in Hong Kong, accounting for about 50% of the shares issued this time</b>(before the exercise of the Over-allotment Option)<b>；</b></li><li><b>International placement of 48.2361 million shares, accounting for approximately 50% of the shares issued this time</b>(before the exercise of the Over-allotment Option)<b>；</b></li></ul><b>In terms of financing purposes,</b>The company's net proceeds of approximately HK $1,263.1 million will be used for the following purposes:</p><p><ul><li>Approximately 88.0% are mainly used for clinical development and commercialization of products;</li><li>8.0% for the construction of GMP compliant in-house production facilities;</li><li>4.0% is used for the company's general corporate and working capital purposes.</li></ul><b>As for financial data,</b>During the Track Record Period, the Company's products have not been approved for commercial sale and therefore did not generate any revenue. Net loss increased from RMB156 million in 2018 to RMB426 million in 2019.</p><p><img src=\"https://static.tigerbbs.com/98eacea48373e0e12e465967c7a1e0a9\" tg-width=\"673\" tg-height=\"811\"></p><p><b>Industry terms,</b>The global oncology drug market has developed significantly over the past few years and is expected to further expand at a faster rate. This is mainly driven by increasing cancer incidence, increasing affordability and technological advancements in treatment modalities.</p><p>The development of targeted therapies has ushered in a new era of tumor treatment characterized by enhanced specificity and efficacy. In addition, other new tumor drug treatments have emerged in recent years and have shown great clinical benefits, including tumor immunotherapy and various combination therapies.</p><p><img src=\"https://static.tigerbbs.com/d174af091109bef09a8e18a14b37491c\" tg-width=\"919\" tg-height=\"430\"></p><p>Among them, SHP2 promotes the proliferation of cancer cells and plays an important role in the process of developing resistance to targeted therapies. SHP2 inhibition as a monotherapy may be effective for cancers with specific alterations. It is estimated that in 2019, the overall annual incidence of patients with advanced solid tumors due to EGFR amplification, KRAS amplification, KRAS G12C mutation, KRASG12A mutation, Class 3 BRAF mutation and NF1 loss of function was approximately 1.2 million and approximately 394,700 worldwide and China, respectively, who are expected to benefit from SHP2-targeted inhibitor monotherapy.</p><p><img src=\"https://static.tigerbbs.com/12672c9f00673ea28225be4042bfacce\" tg-width=\"826\" tg-height=\"524\"></p><p><b>As for cornerstone investors,</b>A number of cornerstone investors agreed to subscribe for the number of Offer Shares available for subscription at the Offer Price, totaling approximately US $60 million, including LAV Funds, Matthews Funds, Hudson's Bay Capital Octagon Investments Master Fund LP, Superstring Capital Master Fund LP and Sage Partners Master Fund.</p><p><b>Company Introduction</b></p><p>It is reported that Garcos, founded in 2015, is a clinical-stage pharmaceutical company focusing on the independent discovery and development of innovative tumor therapies. Its main business focuses on the research of small molecule innovative drugs in the anti-tumor field with independent intellectual property rights, focusing on tumor immunity, drug-resistant antibiotics, geriatric diseases and other directions.</p><p>From the perspective of R&D pipeline, Jiakosi has a total of 16 product pipelines, of which 5 indications and 3 products have entered the clinical stage, and 1 has entered clinical phase IIa. According to the prospectus, the faster-progressing drug development projects in the Garcos product line are SHP2 inhibitors, including JAB-3068 and JAB-3312, of which JAB-3068 has entered Phase IIa.</p><p>It is worth noting that the shareholder lineup of Jiakosi. The company's founder, Dr. Wang Yinxiang, was once<a href=\"https://laohu8.com/S/300558.SZ.SZ\">Beida Pharmaceuticals</a>One of the co-founders of. At the same time, the company is favored by star institutional investors, including Shengde Pharmaceutical Company (holding 17.92% of the shares), Hillhouse Capital (holding 8.57% of the shares), Qiming Venture Capital, Eli Lilly LAV, etc.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","relate_stocks":{"01167":"加科思-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117228784","content_text":"12月18日，加科思公布发售价及配股结果。公告显示，加科思-B每股定价14港元；加科思-B一手中签率15%，申购50手稳中一手。此外，香港公开发售和国际配售均获得超额认购。其中，香港公开认购倍数接近300倍，国际发售认购倍数接近11倍。根据公告，加科思-B共发行9647.61万股，按照每股定价14港元计算，本次IPO净融资为12.63亿港元。若超额配股权全部行使，公司将额外多筹约1.95亿港元，公司股份将于12月21日（下周一）正式交易。分配结果：甲组每手（300股），申购所需资金为4242.32港元；一手中签率15%，申购50手稳中一手；乙组头为45万股（1500手），申购所需资金为6363485.10；乙组头获配21手（6300股），其中321人多获1手。「头锤飞」72张，获配195手（58500股）。招股书显示，加科思发行的9647.61万股中，计划香港公开发售964.8万，占本次发行股份的10%；国际配售8682.81万股，占本次发行股份总数的90%。经回拨机制调整后，有3859.2万股由国际配售回拨至香港公开发售。最终，香港公开发售股份4824万股，约占本次发行股份的50%（超额配股权获行使前）；国际配售4823.61万股，约占本次发行股份的50%（超额配股权获行使前）；筹资用途方面，公司所得款项净额约12.631亿港元将用作以下用途：约88.0%主要用于产品的临床开发及商业化；8.0%用于建造符合GMP标准的内部生产设施；4.0%用于公司的一般企业及营运资金用途。财务数据方面，于往绩记录期间公司的产品尚未获准进行商业销售，因此并无产生任何收益。净亏损由2018年的人民币1.56亿元增加至2019年的人民币4.26亿元。行业方面，全球肿瘤药物市场在过去几年显著发展，并预计将以更快的速度进一步扩展。这主要是由不断增加的癌症发病人数、不断提高的负担能力及治疗模式的技术进步所驱动。靶向疗法的发展开创以增强特异性和疗效为特征的肿瘤治疗新时代。此外近年来出现了其他新的肿瘤药物治疗方式，并已展现出巨大临床益处，其中包括肿瘤免疫疗法和各种联合疗法。其中，SHP2促进癌细胞增殖，并在对靶向疗法产生耐药性的过程中发挥重要作用。SHP2抑制作为单药疗法可能对具有特定改变的癌症有效。据估计，2019年，全球及中国因EGFR扩增、KRAS扩增、KRAS G12C突变、KRASG12A突变、第3类BRAF突变及NF1功能缺失的晚期实体瘤患者的整体年发病人数分别为约1.2百万人和约394,700人，该等患者有望从SHP2靶向抑制剂单药疗法中受益。基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约6000万美元，包括LAV Funds、Matthews Funds、哈德逊湾资本、Octagon Investments Master Fund LP、Superstring Capital Master Fund LP及Sage Partners Master Fund。公司介绍据悉，加科思成立于2015年，是一家临床阶段制药公司，专注于创新肿瘤疗法的自主发现和开发，主营业务聚焦在具有自主知识产权的抗肿瘤领域的小分子创新药研究，重点关注肿瘤免疫、耐药抗菌素、老年病等方向。从研发管线来看，加科思的产品管线共计16项，其中5项适应症共计3个产品进入临床阶段，1项已进入临床Ⅱa期。根据招股书显示，加科思产品线中进展较快的药物开发项目为SHP2抑制剂，包括JAB-3068和JAB-3312，其中JAB-3068已进入IIa期。值得注意的是加科思的股东阵容，公司创始人王印祥博士曾是贝达药业的联合创始人之一。同时，公司受到明星机构投资者的青睐，包括晟德大药厂（持股17.92%）、高瓴资本（持股8.57%）、启明创投、礼来LAV等。","news_type":1,"symbols_score_info":{"01167":0.9}},"isVote":1,"tweetType":1,"viewCount":3407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}